Literature DB >> 15881517

Adjunctive role of cardiovascular magnetic resonance in the assessment of patients with inferior attenuation on myocardial perfusion SPECT.

Jane A McCrohon1, Jonathan C Lyne, Shelley L Rahman, Christine H Lorenz, S Richard Underwood, Dudley J Pennell.   

Abstract

PURPOSE: Inferior attenuation is a common problem in the interpretation of myocardial perfusion SPECT. We explored whether cardiovascular magnetic resonance (CMR) was a useful adjunct in differentiating between artifactual attenuation of the inferior wall and the presence of myocardial infarction and/or ischemia.
METHODS: We used CMR to assess resting wall motion, myocardial perfusion, and the presence of infarction with late gadolinium enhancement in 30 patients with presumed inferior attenuation on ungated myocardial perfusion SPECT, but where uncertainty was present over interpretation of the inferior wall. Perfusion CMR was analyzed visually and quantitatively.
RESULTS: In 23 patients (77%), CMR excluded infarction or ischemia in the inferior wall. The myocardial perfusion reserve index (MPR1) was the same in the inferior and remote myocardium (1.74 +/- 0.43 vs. 1.77 +/- 0.50, p = 0.61). Coronary angiography was performed in 11 of these patients, and was normal in all cases. In the remaining seven subjects (23%), significant abnormality was detected by CMR (infarction, 5; wall motion abnormality, 3; perfusion defect, 5). In these patients, the MPR1 was reduced in the inferior myocardium compared with remote (1.07 +/- 0.19 vs. 1.74 +/- 0.49, p = 0.04). Coronary angiography was performed in three of these patients, revealing significant coronary disease in the artery supplying the inferior territory in all patients.
CONCLUSION: Approximately one-quarter of patients with inferior attenuation on ungated, nonattenuation corrected myocardial perfusion SPECT have abnormalities on CMR. CMR can readily distinguish between artifact, ischemia, and infarction in these cases and in some cases might obviate the need for diagnostic coronary angiography.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15881517     DOI: 10.1081/jcmr-200053627

Source DB:  PubMed          Journal:  J Cardiovasc Magn Reson        ISSN: 1097-6647            Impact factor:   5.364


  5 in total

Review 1.  Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy.

Authors:  Jenna Dean; Sherwin Dela Cruz; Puja K Mehta; C Noel Bairey Merz
Journal:  Nat Rev Cardiol       Date:  2015-05-26       Impact factor: 32.419

2.  Disappearance of myocardial perfusion defects on prone SPECT imaging: comparison with cardiac magnetic resonance imaging in patients without established coronary artery disease.

Authors:  Bo Hedén; Eva Persson; Marcus Carlsson; Olle Pahlm; Håkan Arheden
Journal:  BMC Med Imaging       Date:  2009-08-10       Impact factor: 1.930

3.  Myocardial viability by contrast-enhanced cardiovascular magnetic resonance in patients with coronary artery disease: comparison with gated single-photon emission tomography and FDG position emission tomography.

Authors:  Yen-Wen Wu; Eiji Tadamura; Shotaro Kanao; Masaki Yamamuro; Akira Marui; Masashi Komeda; Masanao Toma; Takeshi Kimura; Kaori Togashi
Journal:  Int J Cardiovasc Imaging       Date:  2007-03-16       Impact factor: 2.357

4.  Diagnostic accuracy of quantitative cardiac MRI evaluation compared to stress single-photon-emission computed tomography.

Authors:  Hideki Futamatsu; Chris Klassen; Marco Pilla; Norbert Wilke; Dominick J Angiolillo; Stuart Smalheiser; Alan Siuciak; Nobuaki Suzuki; Theodore A Bass; Marco A Costa
Journal:  Int J Cardiovasc Imaging       Date:  2007-09-11       Impact factor: 2.357

5.  Late gadolinium uptake demonstrated with magnetic resonance in patients where automated PERFIT analysis of myocardial SPECT suggests irreversible perfusion defect.

Authors:  Lene Rosendahl; Peter Blomstrand; Jan L Ohlsson; Per-Gunnar Björklund; Britt-Marie Ahlander; Sven-Ake Starck; Jan E Engvall
Journal:  BMC Med Imaging       Date:  2008-12-12       Impact factor: 1.930

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.